Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q1 FY2017 Earnings Presentation
20 slides from Lincoln Pharmaceuticals's earnings presentation, August 2016
Slide 1: Q1 FY2017 Earnings Presentation
Providing Affordable and Innovative medicines for healthier lives Q1 FY2017 Earnings Presentation August 2016
Slide 2: Highlights
Highlights Q1 FY2017 vs. Q1 FY2016 Management Perspective o Net Revenue of Rs. 927 million, up 22.5% “After a stellar performance in the fiscal year 2016, we started FY2017 on strong note. Our topline increased by 22.5% y-o-y and o EBITDA of Rs. 181 million, up 57.7% PAT improved significantly by 67
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q1 y-o-y Q4 q-o-q Particulars (Rs. million) FY2017 FY2016 Growth (%) FY2016 Growth (%) Net Revenue 927 757 22.5% 1,285 (27.9)% EBITDA 181 114 57.7% 115 56.6% Margin (%) 19.5% 15.1% 9.0% Profit Before Tax (PBT) 146 83 75.1% 62 136.6% Margin (%)
Slide 4: Revenue Breakup by Therapeutic Area and Geography
Performance Overview Revenue Breakup 2.1% 0.9%1.9% 2% 1% 1.0% 3% 2.0% 1% General Anti Infectives 5% 1.0% 0.6% 3.0% 23% 6.4% Respiratory Systems 24.9% 5.0% Therapeutic Area 11% 25.0% Alimentary Tract and Metabolism 11.0% 18.6% 13% Genito Urinary System and Sex Hormones 22% Musculo-Skeletal System Q1
Slide 5: Performance Trend
Performance Trend Net Revenue (Rs. Million) and Y-o-Y Growth (%) Highlights 54.1% 59.9% 63.6% 22.2% 22.5% o Robust performance of exports business benefited our top-line 757 954 1,080 1,285 927 Q1 FY16 Q2 FY16 Q3 FY16 Q4 FY16 Q1 FY17 o Export increased by 77.8% y-o-y to reach Rs. 3,370 million; expo
Slide 6: Performance Trend
Performance Trend Net Debt / LTM EBITDA Total Debt / Net Worth 1.72x 0.54x 1.54x 0.51x 0.47x 0.47x 0.48x 1.33x 1.16x 1.04x Q1 FY16 Q2 FY16 Q3 FY16 Q4 FY16 Q1 FY17 Q1 FY16 Q2 FY16 Q3 FY16 Q4 FY16 Q1 FY17 ROCE1 RONW2 22.5% 18.9% 19.3% 19.9% 16.9% 15.9% 15.7% 16.3% 13.4% 13.4% Q1 FY16 Q2 FY16 Q3 FY16 Q
Slide 7: Leverage Profile
Leverage Profile (Rs. million) 30-Jun-2016 31-Mar-2016 Long Term Debt 183 235 Credit Rating Short Term Debt 528 526 o The Company’s debt facilities have been assigned Total Debt 711 761 the following ratings by CRISIL Long term bank facilities: A- Less: Cash & Cash Equivalents 143 126 Short term
Slide 8: Strategic Initiatives
Strategic Initiatives 1 New Launches – Domestic Market • In FY2017, the Company plans to increase its marketing team by another 100 people • Also plans to introduce 10 more new products across therapeutic areas 2 Update on Manufacturing Facilities • Tablet capacity almost doubled; atomization has be
Slide 9: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 2.0% 2.7% 1.6% 80 73 Senior Scientist 15 34 Junior Scientist 18 Analysts 18 FY14 FY15 FY16 Regulatory Personnel 12 Administrative Personnel 9 Others 6 Total 78 9
Slide 10: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company 15+ 44th 773 Registered Dossiers Rank in AIOCD Therapeutic Areas July 2014 in covered markets 580 Ongoing Applications 1,500+ 500+ Registered Products SKUs 5,000 Stockiest 300+ 22 C&F Agents Formulations Developed 4 Patents Granted 30+ 550 Field Staff 25 Patents Appl
Slide 11: Key Milestones
Key Milestones Received WHO – GMP Becomes Public Covered 80% of all Developed & for plant/production Limited Company India Market Launched 3 NDDS unit from a Partnership products 2014-15 2001 2010-11 1997-98 2000 1990 1995-96 1984-85 1979 1979 Started export to R&D Center started; Tanzania and Domes
Slide 12: Global Footprint
Global Footprint Presence over 50 countries in Latin America, Africa and Asia Pacific; 22 states across India Jammu Uttaranchal Chandigarh Delhi Ambala Ghaziabad Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada Chennai Latin & Central America : East & We
Slide 13: Best-in-Class Facilities
Best-in-Class Facilities Certifications: WHO-GMP Certified; ISO9001:2008 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for energy saving Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Capacity U
Slide 14: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Anti Allergic / Anti-asthmatics Others* ᵦ- lactams Gyneacologial Products Analgesic / Anti-pyretic Therapies covered Gastro Intestinal Range Anti-bacterial / Anti-viral Vitamins / Minerals / Anti-malarial Anti-oxidants * Other therapies include An
Slide 15: Key Brands – Domestic Markets
Key Brands – Domestic Markets Each squirts (spray) delivers 2 mg Ondansetron Hydrochloride Paracetamol 500 mg + Phenylephrine 5 mg + Diphenhydramine 25 mg + Caffeine 30 mg Tablets 2 Caroverine 160 mg/8 ml 1 3 Injection Natural micronized Effective Anti- Malarial Kingping 12 4 progesterone 300 mg SR
Slide 16: Key Brands – International Markets
Key Brands – International Markets 1000 mg programmed release Paracetamol PROGLETS Meloxicam Suppositories 15 mg 2 1 3 Artesunate 60 mg Injectable Anti Cold Capsules 12 4 Glimepiride 1mg/2 ml Tablets 11 5 α-β Arteether Injection 150mg/ 2 ml Clotrimazole 2% w/w Cream 10 6 Ibuprofen 50 mg + Paracetamo
Slide 17: Key Recent Developments
Key Recent Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better pati
Slide 18: Key Recent Developments
Key Recent Developments o Arteether injection 150 mg/ml • Unique low-viscosity sterile formulation for malaria • Less painful and low volume (1 ml) IM formulation • Convenient patient administration • Patented technology o Namcold DX • First time in India: ‘Extended Release’ Oral Suspension • The on
Slide 19: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 20: Corporate Office: Lincoln Pharmaceuticals Limited
Corporate Office: Lincoln Pharmaceuticals Limited CIN: L24230GJ1995PLC024288 Lincoln House B/h Satyam Complex, Science City Road Sola, Ahmedabad – 380 062 Phone: +91 79 6777 8000 Fax:+91 79 6777 8062 E-mail: [email protected] KP Sompura, Finance Head [email protected] Lincoln Pharmace
Lincoln Pharmaceuticals — Q1 FY2017 Earnings Presentation on 6ix